Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Prev Med. 2014 Jul 16;67:82–88. doi: 10.1016/j.ypmed.2014.07.013

Non-compliance with the initial screening exam visit in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

Pamela M Marcus a, Sheryl L Ogden b, Lisa H Gren c, Jeffery C Childs d, Shannon M Pretzel e, Lois E Lamerato f, Kayo Walsh g, Heather M Rozjabek a,h, Jerome Mabie i, Brett Thomas i, Tom Riley i
PMCID: PMC4167539  NIHMSID: NIHMS617795  PMID: 25038532

Abstract

Objective

Identify predictors of non-compliance with first round screening exams in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Method

PLCO was conducted from 1993–2011 at 10 US institutions. A total of 154,897 healthy men and women ages 55–74 years were randomized. Intervention arm participants were invited to receive gender-appropriate screening exams for prostate, lung, colorectal and ovarian cancer. Using intervention-arm data (73,036 participants), non-compliance percentages for 13 covariates were calculated, as were unadjusted and adjusted odds ratios (ORs), and 95% confidence intervals. Covariates included demographic factors as well as factors specific to PLCO (e.g., method of consent, distance from screening center).

Results

The rate of non-compliance was 11% overall but varied by screening center. Significant associations were observed for most covariates but indicated modest increases or decreases in odds. An exception was use of a two-step consent process (consented intervention arm participants for exams after randomization) relative to a one-step process (consented all participants prior to randomization) (OR: 2.2, 95% CI: 2.0–2.5). Non-compliance percentages increased with further distance from screening centers, but ORs were not significantly different from 1.

Conclusions

Many factors modestly influenced compliance. Consent process was the strongest predictor of compliance.

Keywords: Mass screening, adherence, compliance, cancer, randomized controlled trial as subject

BACKGROUND

The success of randomized controlled trials (RCTs) depends upon many accomplishments, including meeting or exceeding pre-specified levels of compliance with interventions. Failure to meet compliance goals can reduce statistical power, which may necessitate recruitment of more participants than originally planned or extension of follow-up. These changes can be deleterious, particularly if funds are not available for unanticipated activities or the pool of potential participants has become limited. Therefore, it is critical to identify characteristics that affect compliance.

Patient-related predictors of compliance with therapeutic drug regimens for cancer, both in experimental and community-based settings, have been studied extensively, demonstrating the clinical community’s recognition of the importance of compliance when patients or subjects are ill. Compliance with chemopreventive regimens has been reported for RCTs of persons at above-average risk of cancer of the breast [1,2] and lung [3], as well as RCTs like the Women’s Health Initiative, which enrolled average risk women and had breast and colon cancer as primary endpoints [4]. Predictors of screening regimen compliance in RCTs of persons at average risk who reside in the developed world have been published for only one trial (the UK flexible sigmoidoscopy trial) [5]1, but only race and attitudes concerning colorectal cancer and screening for that cancer were examined. Also, this trial randomized persons prior to consenting them for screening exams, and thus did so without their knowledge.

To explore multiple predictors of compliance in mass screening RCTs conducted in the US, we analyzed data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO), an RCT of cancer screening efficacy in men and women ages 55–74 years [7]. Roughly half the 154,897 participants were randomly assigned to an intervention arm and offered specific screening exams multiple times during their first six years of enrollment. These exams required a clinic visit that included a blood draw and, at certain study visits, other invasive and non-invasive clinical procedures.

METHODS

The PLCO Trial

PLCO, a multiphasic RCT, began in 1992, enrolled participants through mid-2001, screened through 2006, and followed each participant until withdrawal, death, 13 years of follow-up, or December 31, 2009 (whichever occurred first) [7]. Final primary results were published in 2011 and 2012 [811]. A total of 154,897 participants, aged 55–74 years at entry, were enrolled at one of ten screening centers nation-wide and were randomized to either an intervention or control arm [12]. At baseline, control arm participants were advised to receive their usual medical care, and intervention arm participants were offered a blood-based PSA exam and digital rectal exam (prostate, men only), a single view chest x-ray (lung), a flexible sigmoidoscopy (colorectal), and a blood-based CA-125 exam and transvaginal ultrasound (ovarian, women only). For prostate and ovarian cancer, blood-based exams were offered annually for five more years, and invasive exams were offered annually for three more years. For lung cancer, ever smokers were offered chest x-ray annually for three more years; never smokers were offered that test annually for two more years. For colorectal cancer, one additional flexible sigmoidoscopy was offered at either year 3 or 5, with year of exam dependent on date of enrollment due to a mid-study protocol change. In almost all instances, all exams for a given study year were performed at a single clinic visit that lasted no more than 2 hours. All screening exams were offered at no cost to the participant; some screening centers provided gas cards or taxi vouchers to offset the cost of transportation to the screening center. Either at or prior to the first screening visit, participants were asked to complete the Baseline Questionnaire Form (BQF), which was gender-specific and queried participants about numerous factors, including demographics, prior and current health history, and family history of cancer.

Informed consent

All screening centers received Institutional Review Board approval to conduct trial activities. Two methods of consent were used: single and dual. Seven centers used a single consent process, which consented for enrollment and randomization at the same time. The remaining three (Henry Ford Health System, Washington University School of Medicine, and Pacific Health Research and Education Institute) initially used a dual consent process. This process began with consent for administration of the BQF and follow-up for cancer incidence and vital status. Consented participants were then randomized, without their knowledge, to the intervention or control arm, and only participants randomized to the intervention arm were told of their assignment; they also received a second consent, which consented for administration of screening exams. The single consent method was expected to increase compliance in the intervention arm but lead to contamination in the control arm; the dual consent method, while expected to decrease participation in the intervention arm, was expected to decrease contamination in the control arm. Contamination refers to the receipt of the screening exams under study by control arm participants. Because the rate of refusal to participate among dual-consent participants randomized to the intervention arm was unacceptably high, the three screening centers switched to the single consent process, with two switching in 1995 and one in 1997.

Compliance

We examined compliance with the first screening round, because all intervention arm participants were offered all screening exams. We chose not to create a compliance index that reflected compliance across study years for a number of reasons: participant relocation, changes in eligibility for exams due to protocol changes and cancer diagnoses, and expected-to-be important compliance predictors, such as declining health status, for which we had no or incomplete data. Participants were classified as non-compliant if no screening exams were completed within 11 months of randomization, and compliant otherwise.

Analysis

All intervention arm participants who did not die or withdraw between randomization and the first screening visit were included in our analyses, although we excluded those who did not complete the BQF or omitted an answer for at least one of the questions under consideration. We examined the relationship between non-compliance and age at randomization, gender, race, educational attainment, body mass index (BMI), presence or history of a co-morbidity at baseline (bronchitis, cirrhosis, diabetes, emphysema, heart attack, hepatitis, stroke, or personal history of cancer), smoking status, marital status, occupation at baseline, family history of a PLCO cancer, screening center, consent type, and year of randomization. The three screening centers (University of Colorado Anschutz Medical Campus, Henry Ford Health System, University of Utah Health Sciences Center) with an interest in the relationship of travel distance and non-compliance used Mapquest.com to calculate, for 1500 randomly selected participants who were eligible for the first screening visit (500 at each center), the distance from the participants’ baseline home addresses to the screening center. Distance was categorized using screening center-specific tertile values due to variation in population density in the catchment areas of the three centers. We used logistic regression models to calculate both unadjusted and adjusted odds ratios. SAS statistical software (Version 9) was used for all statistical analyses.

RESULTS

Entire cohort

Of the 77,445 participants randomized to the intervention arm, 77,436 were eligible for the first screening visit. Our analyses included the 73,036 participants with complete covariate information, or 94% of those eligible for the first screening visit. The average rate of non-compliance in this group was 11%. Rates of non-compliance varied by screening center: they were very low at the University of Alabama at Birmingham (2%) and the University of Minnesota School of Public Health (2%) screening centers, but high at the Henry Ford Health System screening center (26%). For factors other than screening center, the lowest non-compliance rates were observed for males (8%), participants with college degrees or post-graduate training (8%), and persons enrolled using the single consent method (9%); the highest non-compliance rates were observed for participants enrolled using the dual method (29%), participants with a BMI of 18.5 or less (21%) and participants who classified their occupational status as disabled/extended sick leave (20%). (Table 1)

Table 1.

Non-compliance by baseline characteristics in PLCO (10 US screening centers; 1993–2011)

All Sampled for distance questions

Eligible* for any T0 screen Compliant Not compliant Eligible* for any T0 screen Compliant Not compliant

N N % N % N N % N %

All intervention arm participants 77,436 67,466 87.1 9970 12.9 1500 1223 81.5 277 18.5

Complete covariate information 73,036 65,243 89.3 7793 10.7 1425 1176 82.5 249 17.5

Characteristics

Age at randomization (years)
  Younger than 59 24,450 21,932 89.7 2518 10.3 425 349 82.1 76 17.9
  60–64 22,470 20,201 89.9 2269 10.1 465 393 84.5 72 15.5
  65–69 16,413 14,631 89.1 1782 10.9 315 263 83.5 52 16.5
  70 or older 9703 8479 87.4 1224 12.6 220 171 77.7 49 22.3

Gender
  Female 36,998 32,213 87.1 4785 12.9 755 606 80.3 149 19.7
  Male 36,038 33,030 91.7 3008 8.3 670 570 85.1 100 14.9

Race
 White, non-Hispanic 64,756 58,160 89.8 6596 10.2 1230 1018 82.8 212 17.2
 Black, non-Hispanic 3623 3059 84.4 564 15.6 109 84 77.1 25 22.9
 Hispanic 1358 1154 85.0 204 15.0 70 61 87.1 9 12.9
 Asian 2719 2399 88.2 320 11.8 8 8 100 0 .
 Pacific Islander 384 310 80.7 74 19.3 0 . . 0 .
 American Indian 196 161 82.1 35 17.9 8 5 62.5 3 37.5

Education
 Less than high school 5305 4490 84.6 815 15.4 119 84 70.6 35 29.4
 High school grad 16,692 14,732 88.3 1960 11.7 304 248 81.6 56 18.4
 Post HS/some college 25,109 22,248 88.6 2861 11.4 516 423 82.0 93 18.0
 College grad/postgrad 25,930 23,773 91.7 2157 8.3 486 421 86.6 65 13.4

BMI (kg/m^2)
  0 – 18.5 552 439 79.5 113 20.5 10 8 80.0 2 20.0
  18.6 – 25.0 23,950 21,273 88.8 2677 11.2 467 377 80.7 90 19.3
  25.1 – 30.0 30,792 27,771 90.2 3021 9.8 613 527 86.0 86 14.0
  > 30 17,742 15,760 88.8 1982 11.2 335 264 78.8 71 21.2

Comorbidity score
  No 52,994 47,879 90.3 5115 9.7 1003 847 84.4 156 15.6
  Yes 20,042 17,364 86.6 2678 13.4 422 329 78.0 93 22.0

Cigarette smoking status
  Never smoker 34,207 30,799 90.0 3408 10.0 699 592 84.7 107 15.3
  Current smoker 7792 6622 85.0 1170 15.0 153 115 75.2 38 24.8
  Former smoker 31,037 27,822 89.6 3215 10.4 573 469 81.8 104 18.2

Marital status
 Married/living as married 55,450 50,205 90.5 5245 9.5 1082 895 82.7 187 17.3
 Formerly married 15,111 12,897 85.3 2214 14.7 303 251 82.8 52 17.2
 Never married 2475 2141 86.5 334 13.5 40 30 75.0 10 25.0

Current occupation
  Homemaker 8303 7252 87.3 1051 12.7 177 133 75.1 44 24.9
  Working 29,381 26,438 90.0 2943 10.0 527 442 83.9 85 16.1
  Unemployed 757 643 84.9 114 15.1 11 9 81.8 2 18.2
  Retired 31,326 28,136 89.8 3190 10.2 641 542 84.6 99 15.4
  Disabled /extended sick leave 1704 1360 79.8 344 20.2 32 21 65.6 11 34.4
  Other 1565 1414 90.4 151 9.6 37 29 78.4 8 21.6

Family history of PLCO cancer
  Yes 20,470 18,530 90.5 1940 9.5 393 326 83.0 67 17.0
  No 50,808 45,177 88.9 5631 11.1 991 819 82.6 172 17.4
  Possibly 1758 1536 87.4 222 12.6 41 31 75.6 10 24.4

Screening center**
  Colorado 6194 5351 86.4 843 13.6 480 411 85.6 69 14.4
  Georgetown 3470 3335 96.1 135 3.9 0 0 . 0 .
  Pacific Health 4992 4271 85.6 721 14.4 0 0 . 0 .
  Henry Ford 11,585 8573 74.0 3012 26.0 448 311 69.4 137 30.6
  Minnesota 12,786 12,512 97.9 274 2.1 0 0 . 0 .
  Washington University 7333 6371 86.9 962 13.1 0 0 . 0 .
  Pittsburgh 8405 7855 93.5 550 6.5 0 0 . 0 .
  Utah 7144 6526 91.3 618 8.7 497 454 91.3 43 8.7
  Marshfield 8074 7454 92.3 620 7.7 0 0 . 0 .
  Alabama 3053 2995 98.1 58 1.9 0 0 . 0 .

Consent type
  Single 65,971 60,210 91.3 5761 8.7 1075 954 88.7 121 11.3
  Dual 7065 5033 71.2 2032 28.8 350 222 63.4 128 36.6

Randomization year
  1993–1994 7950 7244 91.1 706 8.9 221 190 86.0 31 14.0
  1995–1996 24,563 21,572 87.8 2991 12.2 541 408 75.4 133 24.6
  1997–1998 22,330 19,865 89.0 2465 11.0 397 346 87.2 51 12.8
  1999–2000 16,855 15,382 91.3 1473 8.7 248 216 87.1 32 12.9
  2001 1338 1180 88.2 158 11.8 18 16 88.9 2 11.1

Distance from screening center
  Tertile 1 N/A N/A N/A N/A N/A 478 410 85.8 68 14.2
  Tertile 2 476 391 82.1 85 17.9
  Tertile 3 471 375 79.6 96 20.4
*

Excludes participants who withdrew or died between randomization and the first screening visit.

**

Complete names and locations of screening centers can be found in the Funding section of this manuscript.

Unadjusted odds ratios for consent type, race, smoking status, and occupation were attenuated after adjustment for all variables in multivariate logistic regression models. In some instances, adjustment resulted in a change from a statistically significant association to one that was not. An example is the odds of non-compliance for Black, non-Hispanic participants: the unadjusted odds ratio was 1.6 (95% CI: 1.5–1.8) and the adjusted odds ratio was 0.9 (95% CI: 0.8–1.0). (Table 2)

Table 2.

Odds ratios (OR) and 95% confidence intervals (CI) of non-compliance according to baseline characteristics in PLCO (10 US screening centers; 1993–2011)

% Non-compliant Unadjusted* OR (95% CI) Adjusted*,** OR (95% CI)

Age at randomization (years)
 Younger than 50 10.3 Reference Reference
 60–64 10.1 1.0 (0.9–1.0) 1.0 (0.9–1.1)
 65–59 10.9 1.1 (1.0–1.1) 1.1 (1.0–1.2)
 70 or older 12.6 1.3 (1.2–1.4) 1.3 (1.2–1.4)

Gender
 Female 12.9 Reference Reference
 Male 8.3 0.6 (0.6–0.6) 0.7 (0.7–0.8)

Race
 White, non-Hispanic 10.2 Reference Reference
 Black, non-Hispanic 15.6 1.6 (1.5,1.8) 0.9 (0.8–1.0)
 Hispanic 15.0 1.6 (1.3–1.8) 1.1 (0.9–1.3)
 Asian 11.8 1.2 (1.0–1.3) 0.8 (0.6–0.9)
 Pacific Islander 19.3 2.1 (1.6–2.7) 1.2 (0.9–1.6)
 American Indian 17.9 1.9 (1.3–2.8) 1.2 (0.8–1.8)

Education
 Less than high school 15.4 1.4 (1.2–1.5) 1.2 (1.1–1.3)
 High school grad 11.7 Reference Reference
 Post HS/some college 11.4 1.0 (0.9–1.0) 1.0 (0.9–1.0)
 College grad/postgrad 8.3 0.7 (0.6–0.7) 0.8 (0.7–0.8)

BMI (kg/mˆ2)
 0 – 18.5 20.5 2.0 (1.7–2.5) 1.6 (1.3–2.0)
 18.6 – 25.0 11.2 Reference Reference
 25.1 – 30.0 9.8 0.9 (0.8–0.9) 1.0 (0.9–1.0)
 > 30 11.2 1.0 (0.9–1.1) 1.0 (0.9–1.0)

Comorbidity score
 No 9.7 Reference Reference
 Yes 13.4 1.4 (1.4–1.5) 1.3 (1.2–1.4)

Cigarette smoking status
 Never smoker 10.0 Reference Reference
 Current smoker 15.0 1.6 (1.5–1.7) 1.3 (1.2–1.4)
 Former smoker 10.4 1.0 (1.0–1.1) 1.1 (1.0–1.1)

Marital status
 Married/living as married 9.5 Reference Reference
 Formerly married 14.7 1.6 (1.6–1.7) 1.3 (1.2–1.3)
 Never married 13.5 1.5 (1.3–1.7) 1.3 (1.2–1.5)

Current occupation
 Working 10.0 Reference Reference
 Homemaker 12.7 1.3 (1.2–1.4) 1.0 (0.9–1.1)
 Unemployed 15.1 1.6 (1.3–2.0) 1.3 (1.1–1.7)
 Retired 10.2 1.0 (1.0–1.1) 0.9 (0.9–1.0)
 Disabled/extended sick leave 20.2 2.3 (2.0–2.6) 1.5 (1.3–1.8)
 Other 9.6 1.0 (0.8–1.1) 0.9 (0.8–1.1)

Family history of a PLCO cancer
 No 11.1 Reference Reference
 Yes 9.5 0.8 (0.8–0.9) 0.8 (0.8–0.9)
 Possibly 12.6 1.2 (1.0–1.3) 1.1 (1.0–1.3)

Screening center***
 Colorado 13.6 Reference Reference
 Georgetown 3.9 0.3 (0.2–0.3) 0.3 (0.2–0.3)
 Hawaii 14.4 1.1 (1.0–1.2) 1.0 (0.9–1.2)
 Henry Ford 26.0 2.2 (2.1–2.4) 1.4 (1.3–1.5)
 Minnesota 2.1 0.1 (0.1–0.2) 0.1 (0.1–0.2)
 Washington 13.1 1.0 (0.9–1.1) 0.8 (0.7–0.9)
 Pittsburgh 6.5 0.4 (0.4–0.5) 0.4 (0.4–0.5)
 Utah 8.7 0.6 (0.5–0.7) 0.6 (0.5–0.6)
 Marshfield 7.7 0.5 (0.5–0.6) 0.5 (0.4–0.5)
 Alabama 1.9 0.1 (0.1–0.2) 0.1 (0.1–0.1)

Consent type
 Single 8.7 Reference Reference
 Dual 28.8 4.2 (4.0–4.5) 2.2 (2.0–2.5)

Randomization year
 1993–1994 8.9 0.7 (0.6–0.8) 0.4 (0.4–0.5)
 1995–1996 12.2 Reference Reference
 1997–1998 11.0 0.9 (0.8–0.9) 0.9 (0.9–1.0)
 1999–2000 8.7 0.7 (0.6–0.7) 0.8 (0.8–0.9)
 2001 11.8 1.0 (0.8–1.1) 0.9 (0.7–1.0)
*

Adjusted for all covariates listed in table

**

Complete names and locations of screening centers can be found in the Funding section of this manuscript.

A number of adjusted odds ratios were significant but indicated modest increases or decreases in risk of non-compliance. A notable exception was use of the dual consent method (OR: 2.2, 95% CI: 2.0–2.5), relative to the single consent method. Significant odds ratios of 1.5 or greater also were observed for those with a BMI of 18.5 or less, relative to those who had a BMI of 18.6–25.0 (OR: 1.6, 95% CI: 1.3–2.0), and those who were disabled or on extended sick leave, relative to those who were working (OR: 1.5, 95% CI: 1.3–1.7). Significant odds ratios less than 1 were observed for Asian participants relative to White, non-Hispanic participants (OR: 0.8, 95% CI: 0.6–0.9), persons with college degrees or post-graduate training relative to those whose highest attained education was high school (OR: 0.8, 95% CI: 0.7–0.8), males (OR: 0.7, 95% CI: 0.7–0.8), and participants randomized in 1993 or 1994 (OR: 0.4, 95% CI: 0.4–0.5) and 1999 or 2000 (OR: 0.8, 95% CI: 0.8–0.9), relative to participants randomized in 1995 or 1996. Many screening centers had significant odds ratios less than 1, as the University of Colorado Anschutz Medical Campus screening center was used as the reference category and had one of the higher rates of non-compliance. (Table 2)

Distance subset

Of the 1500 randomly selected participants for distance analyses, 1425 (95%) had complete covariate information and were included. Non-compliance in the distance subset was 18%, which was the same as non-compliance among the totality of participants from those three centers. Patterns of non-compliance were similar in the subset to those in the entire cohort, although rate of non-compliance for the dual consent method was 37% (OR: 7.4, 95% CI: 3.0–18.3). The non-compliance percentages for the tertiles of distance from the screening center were 14% (nearest), 18% (midrange), and 20% (furthest), respectively. The odds ratios for the midrange and far categories, relative to the bottom tertile, were 1.2 and 1.4, respectively, but neither was significantly different from 1.0 (95% CIs: 0.8–1.8 and 1.0–2.1, respectively).

DISCUSSION

Compliance with PLCO’s first screening visit was nearly 90%. Few factors impacted non-compliance in a more-than-modest manner. Our strongest finding, that a dual-step consent process increased the odds of non-compliance more than two-fold, suggests that willingness to participate in observational research does not guarantee willingness to participate in interventional research, and that processes that consent participants for activities after they are randomized should be carefully considered before use.

The UK flexible sigmoidoscopy trial, which examined the association of compliance and race, observed that relative to whites, blacks were more likely to be compliant and Asians less likely to be compliant, but odds ratios were not significantly different from 1 [5]. These patterns are opposite those in the PLCO cohort. Given the minimal data available for compliance in screening RCTs, we compared our findings to RCTs of cancer chemoprevention. In the CARET trial, a trial of lung cancer conducted in above-average risk males and females, patterns of non-compliance by age and gender were comparable to those seen in PLCO [3]. BCPT, a trial of women at above-average risk of breast cancer, observed patterns similar to those of PLCO for age, smoking status, and education [2]. In the WHI supplemental calcium and vitamin D trial, a study of healthy women that examined multiple endpoints including breast and colorectal cancer, patterns of non-compliance for marital and smoking status were similar to PLCO in terms of direction, but patterns of non-compliance for race (in particular, for African-Americans) and age were not [4]. In the aforementioned chemoprevention studies, magnitude of associations was typically modest, as in our data. The fact that in our data certain unadjusted odds ratios for variables typically thought to be associated with non-compliance, like smoking and race, were attenuated after adjustment indicates that it may be misleading to examine and draw conclusions about these variables in other studies without consideration of factors that correlate with them.

The expected benefit of the dual-consent method was to keep contamination low, but low rates of participation among those randomized to the intervention arm were higher than expected. Therefore, the centers that began with the dual-consent method ultimately changed to the single-consent method. There are two lessons to be learned: that participation in an observational study should not be taken to mean willingness to participate in interventional research, and that it is best for to consent participants for interventional activities, especially those that are invasive, prior to randomization so that non-participation, including non-compliance, is minimized and study power can be maintained. If a situation arises in which a “randomize-before-consent” approach must be used, researchers and study coordinators must go to extra efforts to ensure that trial integrity is not compromised due to non-compliance. The fact that the strength of the association of the dual-consent method and non-compliance was meaningfully attenuated after adjustment suggests that targeted approaches to decrease non-compliance in such situations might be effective.

Our restriction to compliance with the first screen limits the generalizability of our results. Risk of non-compliance is likely to change over time as life events, such as aging, disease development, and change in employment, occur. Our findings, therefore, only are relevant to non-compliance soon after trial enrollment. In addition, the BQF was not designed to capture reasons for non-compliance, so we have no data on factors that are certain to impact non-compliance, such as mobility difficulties and other impediments to traveling to a screening center. We would like to note, however, that in our experience the most important factor is the relationship between participants and study staff, something that is multi-dimensional and thus difficult, if not impossible, to measure.

Strengths of our study include a large sample size, one that allowed us to examine odds of non-compliance for some covariate levels that typically have low prevalence, such as low levels of education. We also were able to include many covariates in multivariate models to account for potential confounding.

CONCLUSIONS

In PLCO, a large multi-phasic cancer screening RCT, many factors significantly influenced non-compliance with the first round of exams, including BMI, employment status, and race, but did so only modestly. A process that consented intervention arm participants for screening exams after randomization increased odds of non-compliance two-fold, suggesting that use of this method should be carefully considered before its implementation.

Table 3.

Odds ratios (OR) and 95% confidence intervals (CI) of non-compliance according to baseline characteristics for the distance subset (3 screening centers) in PLCO (10 US screening centers; 1993–2011) (n=1425)

% Non-compliant Unadjusted* OR (CI) Adjusted*,** OR (CI)

Age at randomization (years)
 Younger than 50 17.9 Reference Reference
 60–64 15.5 0.8 (0.6–1.2) 1.0 (0.7–1.5)
 65–59 16.5 0.9 (0.6–1.3) 1.4 (0.8–2.2)
 70 or older 22.3 1.3 (0.9–2.0) 1.7 (1.0–2.9)

Gender
 Female 19.7 Reference Reference
 Male 14.9 0.7 (0.5–0.9) 0.8 (0.6–1.2)

Race
 White- non-Hispanic 17.2 Reference Reference
 Black, non-Hispanic 22.9 1.4 (0.9–2.3) 0.7 (0.4–1.2)
 Hispanic 12.9 0.7 (0.3–1.4) 0.6 (0.3–1.3)
 Asian 0.0
 Pacific Islander 0.0
 American Indian 37.5 2.9 (0.7–12.1) 1.8 (0.4–8.8)

Education
 Less than high school 29.4 1.8 (1.1–3.0) 1.4 (0.8–2.4)
 High school grad 18.4 Reference Reference
 Post HS/some college 18.0 1.0 (0.7–1.4) 1.1 (0.8–1.7)
 College grad/postgrad 13.4 0.7 (0.5–1.0) 0.9 (0.6–1.4)

BMI (kg/mˆ2)
 0 – 18.5 20.0 1.0 (0.2–5.0) 0.9 (0.2–5.7)
 18.6 – 25.0 19.3 Reference Reference
 25.1 – 30.0 14.0 0.7 (0.5–0.9) 0.7 (0.5–1.0)
 > 30.0 21.2 1.1 (0.8–1.6) 1.0 (0.7–1.4)

Comorbidity score
 No 15.6 Reference Reference
 Yes 22.0 1.5 (1.2–2.0) 1.3 (0.9–1.8)

Cigarette smoking status
 Never smoker 15.3 Reference Reference
 Current smoker 24.8 1.8 (1.2–2.8) 1.4 (0.9–2.4)
 Former smoker 18.2 1.2 (0.9–1.6) 1.0 (0.7–1.4)
 Marital status
 Married/living as married 17.3 Reference Reference
 Formerly married 17.2 1.0 (0.7–1.4) 0.9 (0.6–1.3)
 Never married 25.0 1.6 (0.8–3.3) 1.6 (0.7–3.6)
 Current occupation
 Working 16.1 Reference Reference
 Homemaker 24.9 1.7 (1.1–2.6) 1.3 (0.7–1.9)
 Unemployed 18.2 1.2 (0.2–5.4) 0.9 (0.2–4.7)
 Retired 15.4 1.0 (0.7–1.3) 0.7 (0.5–1.0)
 Disabled/extended sick leave 34.4 2.7 (1.3–5.9) 1.7 (0.7–3.9)
 Other 21.6 1.4 (0.6–3.2) 1.0 (0.4–2.6)

Family history of a PLCO cancer
 No 17.4 Reference Reference
 Yes 17.0 1.0 (0.7–1.3) 1.1 (0.8–1.5)
 Possibly 24.4 1.5 (0.7–3.2) 1.8 (0.8–3.9)

Screening center***
 Colorado 14.4 Reference Reference
 Henry Ford 30.6 2.6 (1.9–3.6) 0.5 (0.2–1.2)
 Utah 8.7 0.6 (0.4–0.8) 0.5 (0.3–0.8)

Consent type
 Single 11.3 Reference Reference
 Dual 36.6 4.5 (3.4–6.1) 7.4 (3.0–18.3)

Randomization year
 1993–1994 14.0 0.5 (0.3–0.8) 0.5 (0.3–0.8)
 1995–1996 24.6 Reference Reference
 1997–1998 12.8 0.5 (0.3–0.6) 1.0 (0.7–1.7)
 1999–2000 12.9 0.5 (0.3–0.7) 1.2 (0.7–2.1)
 2001 11.1 0.4 (0.1–1.7) 1.4 (0.2–7.9)

Distance
 Tertile 1 14.2 Reference Reference
 Tertile 2 17.9 1.3 (0.9–1.9) 1.2 (0.8–1.8)
 Tertile 3 20.4 1.5 (1.1–2.2) 1.4 (1.0–2.1)
*

Bolding indicates statistically significant ORs.

**

Adjusted for all covariates listed in table.

***

Complete names and locations of screening centers can be found in the Funding section of this manuscript.

HIGHLIGHTS.

  • Many factors modestly affected non-compliance with the first screening exam visit

  • The strongest predictor was method of consent

  • Consent after randomization significantly increased non-compliance two-fold.

  • These results are relevant for RCTs of healthy persons ages 55–74

Acknowledgments

The authors thank the PLCO participants and the hundreds of individuals who worked on the trial throughout its course. The authors also wish to acknowledge our colleague and friend, Eduard Gamito (deceased). Ed was the Recruitment/Retention Coordinator at the University of Colorado PLCO site. He conceived the idea for this project, directed the initial work and collaborated with the authors. His inspiration and contributions made this paper possible. We dedicate it to his memory.

FUNDING: Supported by contracts from the Division of Cancer Prevention, National Cancer Institute, to the coordinating center (N01-CN-25476 to Westat, Inc.), the ten screening centers (N01-CN-25514 to the University of Colorado Anschutz Medical Campus (Denver Metro area); N01-CN-25522 to Georgetown University Medical Center (Washington, DC metro area); N01-CN-25515 to Pacific Health Research and Education Institute (Honolulu, HI); N01-CN-25512 to Henry Ford Health System (Detroit, MI); N01-CN-25513 to University of Minnesota School of Public Health (Minneapolis/St. Paul, MN); N01-CN-25516 to Washington University School of Medicine (St. Louis, MO); N01-CN-25511 to University of Pittsburg Medical Center (Pittsburgh, PA) ; N01-CN-25524 to the University of Utah Health Sciences Center (Salt Lake City, UT); N01-CN-25518 to Marshfield Clinic Research Foundation (Marshfield, WI); N01-CN-75022 to University of Alabama at Birmingham (Birmingham, AL); and N02-CN-55203-76 and N02-CN-35001-45 to Information Management Services, Inc. (Rockville, MD).

ABBREVIATIONS

PLCO

Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

BQF

Baseline Questionnaire Form

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1

Results have been published from the French component of the European Randomized Study of Prostate Cancer Screening [6], but are not available in English, and thus are not considered.

CONFLICT OF INTEREST: The authors have no conflicting interests, financial or otherwise.

AUTHOR CONTRIBUTIONS: SLO, LHG, JCC, SMP, LEL were leaders in data collection at PLCO screening centers; along with KW, they identified this research topic and led discussions concerning issues that were important in data analysis. JM, BT, and TR managed data and conducted statistical analysis. PMM provided guidance on research question development and statistical analysis. PMM and SLO led the drafting of this manuscript. HMR created the tables for the manuscript. All authors read and approved the final manuscript.

Contributor Information

Pamela M. Marcus, Email: marcusp@mail.nih.gov.

Sheryl L. Ogden, Email: Sheryl.ogden@ucdenver.edu.

Lisa H. Gren, Email: Lisa.gren@hsc.utah.edu.

Jeffery C. Childs, Email: jeff.childs@hsc.utah.edu.

Shannon M Pretzel, Email: Shannon.pretzel@ucdenver.edu.

Lois E. Lamerato, Email: llamera1@hfhs.org.

Kayo Walsh, Email: walsh@hcp.med.harvard.edu.

Heather M. Rozjabek, Email: heather.rozjabek@gmail.com.

Jerome Mabie, Email: mabiej@imsweb.com.

Brett Thomas, Email: thomasb@imsweb.com.

Tom Riley, Email: rileyt@imsweb.com.

References

  • 1.Land SR, Cronin WM, Wickerham DL, et al. Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial. Cancer Prev Res. 2011;4:1393–400. doi: 10.1158/1940-6207.CAPR-11-0172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Cronin WM, Cecchini RS, Wickerham D, Vogel VG, Costantino JP, Wolmark N. Factors associated with participant adherence in the NSABP study of tamoxifen and raloxifine (STAR). [abstract]. J Clin Oncol; American Society of Clinical Oncology (ASCO) Annual Meeting; 2008; 2008. May 20, abstr 6518. [Google Scholar]
  • 3.Thornquist MD, Patrick DL, Omenn GS. Participation and adherence among older men and women recruited to the Beta-Carotene and Retinol Efficacy Trial. Gerentologist. 1991;5:593–597. doi: 10.1093/geront/31.5.593. [DOI] [PubMed] [Google Scholar]
  • 4.Brunner R, Dunbar-Jacob J, Leboff MS, et al. Predictors of adherence in the Women’s Health Initiative calcium and vitamin D trial. Behav Med. 2009;34:145–55. doi: 10.3200/BMED.34.4.145-155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Robb KA, Power E, Atkin W, Wardle J. Ethnic differences in participation in flexible sigmoidoscopy screening in the UK. J Med Screen. 2008;15:130–6. doi: 10.1258/jms.2008.007112. [DOI] [PubMed] [Google Scholar]
  • 6.Jegu J, Tretarre B, Grosclaude P, et al. Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault. Prog Urol. 2009;17:487–8. doi: 10.1016/j.purol.2009.03.001. [French] [DOI] [PubMed] [Google Scholar]
  • 7.Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21:273S–309S. doi: 10.1016/s0197-2456(00)00098-2. [DOI] [PubMed] [Google Scholar]
  • 8.Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305:2295–303. doi: 10.1001/jama.2011.766. [DOI] [PubMed] [Google Scholar]
  • 9.Oken MM, Hocking WG, Kvale PA, Andriole GL, Buys SS, Church TR, et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA. 2011;306:1865–73. doi: 10.1001/jama.2011.1591. [DOI] [PubMed] [Google Scholar]
  • 10.Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125–32. doi: 10.1093/jnci/djr500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012;366:2345–57. doi: 10.1056/NEJMoa1114635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Gren L, Broski K, Childs J, et al. Recruitment methods employed in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Clin Trials. 2009;6:52–9. doi: 10.1177/1740774508100974. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES